• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Adjuvant gemcitabine improves long-term survival rates of patients with pancreatic cancer

bys25qthea
October 9, 2013
in Chronic Disease, Endocrinology, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Patients with resected pancreatic cancer treated with adjuvant gemcitabine for 6 months had improvements in 5-year and 10-year disease-free survival rates compared to patients without adjuvant therapy. 

2. The overall survival rate improved by 24% in patients with resected pancreatic cancer treated with adjuvant gemcitabine compared to patients without adjuvant therapy. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Patients with pancreatic cancer have poor survival rates due to late detection of disease and cancer poorly responsive to chemotherapy or radiation. Currently no expert consensus exits on adjuvant therapy after pancreatic cancer resection. In this randomized phase 3 trial, patients with macroscopically resected pancreatic cancer were treated with adjuvant gemcitabine therapy for 6 months or observed without therapy. Patients treated with gemcitabine showed an improvement in disease-free survival of 13.4 months (95% CI, 11.6-15.3) compared to 6.7 months (95% CI, 6.0-7.5) in patients who were observed. Overall survival rate improved by 24% with adjuvant therapy, with 10.3% improvement in 5-year survival rate (20.7% vs.10.4%) and 4.5% improvement in 10-year survival (12.2% vs. 7.7%) in gemcitabine vs. control groups respectively The study informs clinical practice by creating a standard for adjuvant therapy for resected pancreatic cancer. Strengths of the study include balanced baseline characteristics between experimental and control groups, as well as broad applicability to both community and academic oncology practices.

Click to read the study, published today in JAMA

RELATED REPORTS

Artificial Intelligence and Real World Data Speed Up Drug Development

#VisualAbstract: Cabozantinib Improved Progression-Free Survival in Advanced Neuroendocrine 2m -m Tumors

#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma

Relevant Reading: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

In-Depth [multi-center, randomized, phase 3 trial]: The study was performed in Germany and Austria between July 1998 and December 2004 with follow-up ending in September 2012. Three-hundred and sixty eight patients with stage T1-4N0-1M0 resected pancreatic cancer were randomized between adjuvant therapy with gemcitabine for 6 months or observation groups. Patients received follow-up every 8 weeks for 5 years to assess for adverse events, disease status, and survival. The primary endpoint of the study was disease-free survival, defined as time from randomization to the first symptoms indicating relapse or tumor detection by diagnostic imaging. A median follow-up of 11 years was established for all patients. Median disease-free survival in patients treated with gemcitabine was 13.4 months (95% CI, 11.6-15.3) compared to 6.7 months (95% CI 6.0-7.5) in controls (HR 0.55, 95% CI 0.44-0.69, p<0.001). Survival rates were also increased with 5-year survival rates of 20.7% vs 10.4%, and 10-year survival rates of 12.2% vs. 7.7% in gemcitabine vs control groups respectively. Adjuvant gemcitabine led to a 24% improvement in overall survival. Besides gemcitabine, other prognostic factors for survival were T and N stage, with the majority of patients in both groups in stage T3N1 before surgical resection.

By Gayatri Boddupalli and Brittany Hasty 

More from this author: Racial differences in breast cancer survival remain large, unchanged, Early surgical intervention for mitral regurgitation associated with greater long-term survival, Sofosbuvir, ribavirin achieve high rates of Hepatitis C virus remission in toughest cases, Growth disorders detected using screening algorithms, Clinical decision rule highly sensitive in predicting SAH in patients with acute nontraumatic headache

 © 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: gemcitabinepancreatic cancer
Previous Post

Sentinel lymph node surgery associated with a high false negative rate in node-positive breast cancer: Alliance Trial

Next Post

New pathogenic dimorphic fungal species suggested in HIV-positive patients

RelatedReports

AI Roundup

Artificial Intelligence and Real World Data Speed Up Drug Development

May 27, 2025
#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer
StudyGraphics

#VisualAbstract: Cabozantinib Improved Progression-Free Survival in Advanced Neuroendocrine 2m -m Tumors

October 1, 2024
#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
StudyGraphics

#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma

October 27, 2023
Single-cycle adjuvant chemotherapy may be effective in stage I testicular cancer
Chronic Disease

Pembrolizumab plus gemcitabine and cisplatin improves survival in advanced biliary tract cancer

June 14, 2023
Next Post
New pathogenic dimorphic fungal species suggested in HIV-positive patients

New pathogenic dimorphic fungal species suggested in HIV-positive patients

Children born late preterm birth at higher odds to fail standardized tests

High-flow nasal cannulae noninferior to nasal CPAP in very preterm infants after extubation

Antepartum and intrapartum events both linked to neonatal HIE

Pregnancy outcomes in kidney transplant recipients encouraging

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.